Sector
PharmaceuticalsOpen
₹1,148.1Prev. Close
₹1,149Turnover(Lac.)
₹2,061.85Day's High
₹1,149.8Day's Low
₹1,13852 Week's High
₹1,181.552 Week's Low
₹835.5Book Value
₹237.3Face Value
₹1Mkt Cap (₹ Cr.)
1,14,044.61P/E
30.99EPS
37Divi. Yield
0.0920 May 2025
12:00 AM
AGM
Announcement Date: 20 May, 2025
8 May 2026
12:00 AM
Board Meeting
Agenda : Audited Result
19 May 2025
12:00 AM
Dividend
Dividend Amount: 11
Record Date: 25 Jul, 2025
Zydus Life stated that it has unveiled the biosimilar under the brand Tishtha™. It can be used for treatment of multiple cancers.
It further added that the company will raise funds via qualified institutional placement (QIP) to part-fund the acquisition.
NUFYMCO is a vascular endothelial growth factor inhibitor designed to treat serious ophthalmic conditions, particularly those affecting retinal health.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Zydus Lifesciences, Intellect Design Arena, etc.
The company plans to manufacture these tablets at its formulation manufacturing facility situated in the SEZ in Ahmedabad.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 100.6 | 100.6 | 100.6 | 101.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23,571.1 | 21,089.5 | 15,615.9 | 13,538.2 |
Net Worth | 23,671.7 | 21,190.1 | 15,716.5 | 13,639.4 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 7,981.9 | 7,780 | 6,347.4 | 5,809.9 |
yoy growth (%) | 2.59 | 22.56 | 9.25 | 79.83 |
Raw materials | -2,870.2 | -2,351.4 | -1,951.7 | -1,695.7 |
As % of sales | 35.95 | 30.22 | 30.74 | 29.18 |
Employee costs | -1,204.9 | -1,147.3 | -1,077.4 | -826 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,483.2 | 1,876 | 1,609.7 | 1,497.2 |
Depreciation | -478.7 | -451.1 | -428.9 | -293.1 |
Tax paid | -306 | -212.3 | -204.1 | -406.4 |
Working capital | 607.49 | 991.9 | 1,239 | 1,462.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.59 | 22.56 | 9.25 | 79.83 |
Op profit growth | -16.91 | 62.23 | -13.55 | 412.7 |
EBIT growth | -16.88 | 5.6 | 18.09 | 138.95 |
Net profit growth | -41.88 | 4.48 | 29.52 | 64.79 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 26,719.7 | 22,573.8 | 19,021.5 | 16,877.8 | 14,827.6 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 26,719.7 | 22,573.8 | 19,021.5 | 16,877.8 | 14,827.6 |
Other Operating Income | 428.7 | 667.7 | 525.9 | 359.6 | 282.3 |
Other Income | 509.5 | 269.5 | 307.1 | 186.6 | 2,583.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,956.4 | 159.44 | 4,69,381.9 | 608.7 | 0.82 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 7,318 | 73.01 | 1,94,374.77 | 756 | 0.41 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 5,005.4 | 76.54 | 1,69,332.71 | 467 | 0.76 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,441.6 | 33.83 | 1,16,446.86 | 384.64 | 0.9 | 3,840.92 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,149 | 30.99 | 1,14,378.78 | 1,722 | 0.09 | 3,564.6 | 237.3 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman(Non Exe)&Dir(Non-Ind)
Pankaj R Patel
Executive Director & MD
Sharvil P Patel
Executive Director
Ganesh N Nayak
Non-Exec & Non-Independent Dir
Mukesh Patel
Independent Non Exe. Director
Bhadresh K Shah
Independent Non Exe. Director
Akhil A. Monappa
Independent Non Exe. Director
Upsana Kamineni
Independent Non Exe. Director
Shelina P. Parikh
Independent Director
Kulin S Lalbhai
Company Sec. & Compli. Officer
Dhaval N Soni
Zydus Corporate Park S No 536,
Khoraj Sarkhej-Gandhinagar H/W,
Gujarat - 382481
Tel: 91-079-26868100
Website: http://www.zyduscadila.com
Email: dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.
5th Floor 506 to 508,
ABC-I Off C G Road, Navrangpura,
Ahmedabad-380009
Tel: 91-79-26465179
Website: https://in.mpms.mufg.com/
Email: ipo.team@linkintime.co.in
Summary
Zydus Lifesciences Limited, formerly known Cadila Healthcare Limited was incorporated in May, 1995. The Company changed the name from Cadila Healthcare Limited to Zydus Lifesciences Limited on Februa...
Read More
Reports by Zydus Lifesciences Ltd
What is the Zydus Lifesciences Ltd share price today?
What is the Market Cap of Zydus Lifesciences Ltd?
What is the PE and PB ratio of Zydus Lifesciences Ltd?
What is the 52 Week High and Low of Zydus Lifesciences Ltd?
What is the CAGR of Zydus Lifesciences Ltd?
What is the shareholding pattern of Zydus Lifesciences Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
